Lyme Disease Treatment Cost and Economic Impact

Lyme disease can create major financial burdens for patients and society.
Costs rise significantly for patients with chronic manifestations or PTLDS.
Productivity losses account for a large portion of the economic impact.

Lyme disease treatment cost can be substantial, particularly for patients with chronic manifestations or Post-Treatment Lyme Disease Syndrome (PTLDS). Researchers examining the economic impact of Lyme disease found that costs extend far beyond antibiotics and office visits. [1]

The cases were identified based on the physicians’ determination in the medical record, patients’ clinical findings, tick exposure, and other relevant details including laboratory results. [1]

---

Cost of Early Lyme Disease

The mean annual cost of early Lyme disease included:

• $801 for direct medical costs
• $259 for indirect medical costs
• $52 for non-medical costs
• $196 for productivity losses

The total mean annual cost for early Lyme disease was approximately $1,310 per patient. [1]

---

Cost of Chronic Manifestations of Lyme Disease

The cost of Lyme disease was significantly higher for individuals with chronic manifestations of the disease.

The mean annual cost for these patients was $16,199 per patient. [1]

These costs included:

• $1,872 for direct medical costs
• $434 for indirect medical costs
• $5,109 for non-medical costs
• $8,785 for productivity losses

The annual per-patient cost of chronic manifestations of Lyme disease exceeded the reported costs for several other chronic illnesses: $10,716 for rheumatoid arthritis [2], $10,911 for fibromyalgia [2], and $13,094 for lupus. [3]

---

PTLDS and Long-Term Functional Impairment

A study by Aucott and colleagues confirmed the high number of Lyme disease patients with persistent symptoms after standard treatment.

Thirty-six percent of individuals treated with 3 weeks of doxycycline for an erythema migrans rash developed Post-Treatment Lyme Disease Syndrome (PTLDS). [4]

“At 6 months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties,” according to Aucott from Johns Hopkins University School of Medicine. “Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS.” [4]

These ongoing symptoms may contribute substantially to lost productivity, reduced work capacity, and long-term healthcare costs.

---

Economic Impact of Lyme Disease in the United States

After reviewing 23,763 cases reported to the Centers for Disease Control and Prevention (CDC) in 2002, Zhang and colleagues concluded that Lyme disease carried a substantial financial burden. [1]

“The estimated nationwide annual economic impact of LD and relevant complaints was ≈$203 million (in 2002 dollars),” according to Zhang. [1]

Zhang also noted that costs would likely be substantially higher if the true number of Lyme disease cases were included in the analysis.

The CDC now estimates there are at least 300,000 new Lyme disease cases annually in the United States.

---

Estimated Societal Cost Using Current CDC Estimates

If the cost estimates described by Zhang are extrapolated using current CDC incidence estimates and PTLDS rates described by Aucott, the societal cost of Lyme disease could exceed $2 billion annually.

Estimated distribution of cases:

• 64% × 300,000 early Lyme disease cases = 192,000
• 36% × 300,000 chronic/late Lyme disease cases = 108,000

Estimated costs:

• $1,310 × 192,000 ≈ $251 million for early Lyme disease
• $16,199 × 108,000 ≈ $1.75 billion for chronic/late Lyme disease

Zhang further cautioned that their estimates likely underestimated the actual burden because costs beyond the study period were not included. [1]

---

Persistent PTLDS May Last for Decades

A study by Weitzner and colleagues found that 11% of individuals experienced PTLDS symptoms for more than a decade following treatment for culture-confirmed early Lyme disease. [5]

The long-term economic impact for patients who remain ill for years or decades remains unknown.

Both women (12.3%) and men (9.9%) continued to experience PTLDS symptoms more than a decade after diagnosis. [5]

---

Clinical Perspective

The economic burden of Lyme disease includes more than direct medical costs. Productivity losses, functional impairment, and persistent symptoms contribute substantially to the overall societal impact.

These findings underscore the importance of timely diagnosis, careful follow-up, and more effective treatment strategies for patients with persistent symptoms.

Delayed recognition or inadequate follow-up may contribute to significant personal and societal costs.

To learn more about persistent symptoms, see persistent Lyme disease mechanisms and Post-Treatment Lyme Disease Syndrome (PTLDS).

---

Frequently Asked Questions

How much does Lyme disease treatment cost?

Costs vary widely. One study estimated approximately $1,310 annually for early Lyme disease and $16,199 annually for chronic manifestations. [1]

Why are chronic manifestations more expensive?

Persistent symptoms may lead to higher medical costs, reduced productivity, disability, and ongoing supportive care needs.

What contributes most to the economic burden?

Productivity losses accounted for a large portion of total costs in patients with chronic manifestations of Lyme disease. [1]

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention